Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study on Adjuvant Treatment of MRD-positive Colorectal Cancer Patients With Routine Chemotherapy Combined With Personalized Immune Regulation Diagnosis and Treatment Technology

NCT06434376 is registered in ClinicalTrials.gov with Second Affiliated Hospital of Wenzhou Medical University as lead sponsor.

NCT NCT06434376
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06434376 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study on Adjuvant Treatment of MRD-positive Colorectal Cancer Patients With Routine Chemotherapy Combined With Personalized Immune Regulation Diagnosis and Treatment Technology
Lead sponsor
Second Affiliated Hospital of Wenzhou Medical University
Phase
Phase 1
Overall status
Enrolling by invitation
Start date
July 1, 2024
Completion date
December 31, 2026
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer